Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H15ClN6O |
| Molecular Weight | 318.761 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(C)C=NC(CN2C=NC3=C(Cl)N=C(N)N=C23)=C1C
InChI
InChIKey=QULDDKSCVCJTPV-UHFFFAOYSA-N
InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20)
| Molecular Formula | C14H15ClN6O |
| Molecular Weight | 318.761 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
BIIB021 binds in the ATP-binding pocket of Hsp90, interferes with Hsp90 chaperone function, and results in client protein degradation and tumor growth inhibition. Hsp90 is overexpressed in many types of cancer and acts to stabilize malignancy producing oncoproteins. Therefore, inhibition of Hsp90 with BIIB021 leads to the degradation of oncoproteins that drive malignancy.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P07900 Gene ID: 3320.0 Gene Symbol: HSP90AA1 Target Organism: Homo sapiens (Human) |
1.7 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1439 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22898035 |
600 mg 1 times / day single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIIB021 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2942 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22898035 |
600 mg 1 times / day single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIIB021 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. | 2007 Jun 14 |
|
| BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. | 2009 Apr |
|
| Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. | 2009 Aug 15 |
Sample Use Guides
In a phase II clinical trial, breast cancer patients were treated with either 100 mg twice daily + exemestane 25 mg once per day for 28 days, or 450 mg three times weekly + exemestane 25 mg once per day.
Route of Administration:
Oral
BIIB021 was investigated as an inhibitor of heat shock protein 90 (Hsp90) alone and in combination with triptolide (TPL) on T-cell acute lymphoblastic leukemia. The cell viability of Human T-ALL cell line Molt-4 was measured using MTT assay. Molt-4 cells were treated with BIIB021 (50-800 nmol/L) which inhibited the cell growth in a dose-dependent manner. The IC50 value was 384.6 and 301.8 nmol/L, respectively, at 48 and 72 h.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:39:53 UTC 2023
by
admin
on
Fri Dec 15 15:39:53 UTC 2023
|
| Record UNII |
851B9FQ7Q0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
848695-25-0
Created by
admin on Fri Dec 15 15:39:53 UTC 2023 , Edited by admin on Fri Dec 15 15:39:53 UTC 2023
|
PRIMARY | |||
|
90687
Created by
admin on Fri Dec 15 15:39:53 UTC 2023 , Edited by admin on Fri Dec 15 15:39:53 UTC 2023
|
PRIMARY | |||
|
DTXSID601025952
Created by
admin on Fri Dec 15 15:39:53 UTC 2023 , Edited by admin on Fri Dec 15 15:39:53 UTC 2023
|
PRIMARY | |||
|
300000041484
Created by
admin on Fri Dec 15 15:39:53 UTC 2023 , Edited by admin on Fri Dec 15 15:39:53 UTC 2023
|
PRIMARY | |||
|
DB12359
Created by
admin on Fri Dec 15 15:39:53 UTC 2023 , Edited by admin on Fri Dec 15 15:39:53 UTC 2023
|
PRIMARY | |||
|
851B9FQ7Q0
Created by
admin on Fri Dec 15 15:39:53 UTC 2023 , Edited by admin on Fri Dec 15 15:39:53 UTC 2023
|
PRIMARY | |||
|
16736529
Created by
admin on Fri Dec 15 15:39:53 UTC 2023 , Edited by admin on Fri Dec 15 15:39:53 UTC 2023
|
PRIMARY | |||
|
C62517
Created by
admin on Fri Dec 15 15:39:53 UTC 2023 , Edited by admin on Fri Dec 15 15:39:53 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
